- Previous Close
4.6100 - Open
4.5300 - Bid 4.6300 x 200
- Ask 4.7600 x 100
- Day's Range
4.3800 - 5.3480 - 52 Week Range
4.3300 - 20.4000 - Volume
608,167 - Avg. Volume
202,880 - Market Cap (intraday)
121.691M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-26.2000 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.00
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.
www.23andme.comRecent News: ME
View More
Performance Overview: ME
Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ME
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ME
View MoreValuation Measures
Market Cap
119.11M
Enterprise Value
23.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.56
Price/Book (mrq)
0.83
Enterprise Value/Revenue
0.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.77%
Return on Equity (ttm)
-154.21%
Revenue (ttm)
199.19M
Net Income Avi to Common (ttm)
-631.48M
Diluted EPS (ttm)
-26.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
169.97M
Total Debt/Equity (mrq)
51.68%
Levered Free Cash Flow (ttm)
-1.55M
Research Analysis: ME
View MoreCompany Insights: ME
ME does not have Company Insights
Research Reports: ME
View MoreDropping Coverage of 23andMe
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Placing 23andMe Under Review
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Initiating Coverage of 23andMe, a Risky Healthcare Technology Company With Substantial Upside
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Rating